Acquired somatic mutations of the PIG-A gene lead to deficient expression of glycosyl-phosphatidyl-inositol-anchored proteins (GPI-AP) by haematopoietic cells and play a causative role in the pathogenesis of paroxysmal nocturnal haemoglobinuria (PNH). However, PIG-A mutations do not explain how the defective PNH clone can expand. It was hypothesized that a selection process conferring a relative advantage to the GPI-AP-deficient population is required. Since GPI-AP-deficient cells are also detectable in a substantial proportion of patients with otherwise typical aplastic anaemia (AA), the mechanisms inducing bone marrow failure might selectively spare the GPI-deficient cells. In order to examine the growth characteristics of GPI-AP-deficient cells in more detail, we performed repeated analyses of GPI-AP expression on peripheral blood cells in 41 patients with AA. We observed four patterns of the course of GPI-AP-deficient populations: (1) 13 patients showed normal expression of GPI-AP in the first analysis and in at least two follow-up studies at a median time of 709 days after the first analysis. (2) Secondary evolution of a GPI-AP-deficient population was a rare event. Only 4 patients with initially normal GPI-AP expression developed a GPI-AP-deficient population during follow up after immunosuppressive treatment. (3) Persistence of GPI-AP-deficient cells was observed in 16 patients during a median follow-up time of 774 days. However, in some patients, the size of the GPI-AP-deficient population increased substantially. (4) Disappearance of a GPI-AP-deficient population was observed in 8 patients. The time course of GPI-AP expression in relation to the treatment suggests that therapeutic interventions might modulate the ratio of normal versus GPI-AP-deficient haematopoiesis. Overall, these data argue against an ‘absolute growth advantage’ of GPI-AP-deficient cells. Our data are consistent with the hypothesis that haematopoietic failure caused by damage to normal haematopoiesis allows the outgrowth of a GPI-AP-deficient population. Thus, in at least some patients GPI-AP-deficient cells might pre-exist at a very low percentage and replace haematopoiesis after an insult to the normal cells.

Keywords:
Aplastic anaemia, Glycosylphosphatidyl-inositol anchor, Paroxysmal nocturnal haemoglobinuria, Pathophysiology, PIG-A gene
1.
Tichelli A, Gratwohl A, Wursch A, et al: Late haematological complications in severe aplastic anaemia. Br J Haematol 1988;69:413–418.
2.
Tichelli A, Gratwohl A, Nissen C, et al: Late clonal complications in severe aplastic anemia. Leuk Lymphoma 1994;12:167–175.
3.
Rosse WF, Ware RE: The molecular basis of paroxysmal nocturnal hemoglobinuria. Blood 1995;86:3277–3286.
4.
Luzzatto L, Bessler M: The dual pathogenesis of paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 1996;3:101–110.
5.
Schrezenmeier H, Hertenstein B, Wagner B, et al: A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phosphatidylinositol glycan anchored proteins. Exp Hematol 1995;23:81–87.
6.
Dunn DE, Tanawattanacharoen P, Boccuni P, et al: Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes (see comments). Ann Intern Med 1999;131:401–408.
7.
Fores R, Alcocer M, Diez Martin JL, et al: Flow cytometric analysis of decay-accelerating factor (CD55) on neutrophils from aplastic anaemia patients. Br J Haematol 1995;90:728–730.
8.
Griscelli Bennaceur A, Gluckman E, Scrobohaci ML, et al: Aplastic anemia and paroxysmal nocturnal hemoglobinuria: Search for a pathogenetic link. Blood 1995;85:1354–1363.
9.
Schubert J, Vogt HG, Zielinska Skowronek M, et al: Development of the glycosylphosphatitylinositol-anchoring defect characteristic for paroxysmal nocturnal hemoglobinuria in patients with aplastic anemia. Blood 1994;83:2323–2328.
10.
Tooze JA, Saso R, Marsh JC, et al: The novel monoclonal antibody By114 helps detect the early emergence of a paroxysmal nocturnal hemoglobinuria clone in aplastic anemia. Exp Hematol 1995;23:1484–1491.
11.
Nissen C, Tichelli A, Gratwohl A, et al: High incidence of transiently appearing complement-sensitive bone marrow precursor cells in patients with severe aplastic anemia: A possible role of high endogenous IL–2 in their suppression. Acta Haematol 1999;101:165–172.
12.
Rotoli B, Luzzatto L: Paroxysmal nocturnal haemoglobinuria. Baillières Clin Haematol 1989;2:113–138.
13.
Rotoli B, Bessler M, Alfinito F, et al: Membrane proteins in paroxysmal nocturnal haemoglobinuria. Blood Rev 1993;7:75–86.
14.
Young NS: The problem of clonality in aplastic anemia: Dr Dameshek’s riddle, restated. Blood 1992;79:1385–1392.
15.
Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al: Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med 1991;324:1297–1304.
16.
Bacigalupo A, Hows J, Gluckman E, et al: Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): A report of the EBMT SAA working party. Br J Haematol 1988;70:177–182.
17.
Raghavachar A, Ganser A, Freund M, et al: Long-term interleukin–3 and intensive immunosuppression in the treatment of aplastic anemia. Cytokines Mol Ther 1996;215–223.
18.
Bessler M, Mason PJ, Hillmen P, et al: Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J 1994;13:110–117.
19.
Bessler M, Mason P, Hillmen P, et al: Somatic mutations and cellular selection in paroxysmal nocturnal haemoglobinuria. Lancet 1994;343:951–953.
20.
Bessler M, Mason PJ, Hillmen P, et al: Mutations in the PIG-A gene causing partial deficiency of GPI-linked surface proteins (PNH II) in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1994;87:863–866.
21.
Miyata T, Takeda J, Iida Y, et al: The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993;259:1318–1320.
22.
Ostendorf T, Nischan C, Schubert J, et al: Heterogeneous PIG-A mutations in different cell lineages in paroxysmal nocturnal hemoglobinuria heterogeneous PIG-A mutations in different cell lineages in paroxysmal nocturnal hemoglobinuria. Blood 1995;85:1640–1646.
23.
Takeda J, Miyata T, Kawagoe K, et al: Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993;73:703–711.
24.
Ware RE, Rosse WF, Howard TA: Mutations within the Piga gene in patients with paroxysmal nocturnal hemoglobinuria. Blood 1994;83:2418–2422.
25.
Yamada N, Miyata T, Maeda K, et al: Somatic mutations of the PIG-A gene found in Japanese patients with paroxysmal nocturnal hemoglobinuria. Blood 1995;85:885–892.
26.
Endo M, Ware RE, Vreeke TM, et al: Molecular basis of the heterogeneity of expression of glycosyl phosphatidylinositol anchored proteins in paroxysmal nocturnal hemoglobinuria. Blood 1996;87:2546–2557.
27.
Lin LI, Liu CH, Chen YC, et al: PIG-A gene mutations in four Taiwanese patients with paroxysmal nocturnal haemoglobinuria following aplastic anaemia. Br J Haematol 1997;97:286–292.
28.
Nafa K, Mason PJ, Hillmen P, et al: Mutations in the PIG-A gene causing paroxysmal nocturnal hemoglobinuria are mainly of the frameshift type. Blood 1995;86:4650–4655.
29.
Nagarajan S, Brodsky RA, Young NS, et al: Genetic defects underlying paroxysmal nocturnal hemoglobinuria that arises out of aplastic anemia. Blood 1995;86:4656–4661.
30.
Nishimura J, Inoue N, Wada H, et al: A patient with paroxysmal nocturnal hemoglobinuria bearing four independent PIG-A mutant clones. Blood 1997;89:3470–3476.
31.
Savoia A, Ianzano L, Lunardi C, et al: Identification of three novel mutations in the PIG-A gene in paroxysmal nocturnal haemoglobinuria (PNH) patients. Hum Genet 1996;97:45–48.
32.
Nakao S, Yamaguchi M, Takamatsu H, et al: Expansion of a paroxysmal nocturnal hemoglobinuria (PNH) clone after cyclosporine therapy for aplastic anemia/PNH syndrome (letter; comment). Blood 1992;80:2943–2944.
33.
Hillmen P, Hows JM, Luzzatto L: Two distinct patterns of glycosylphosphatidylinositol (GPI) linked protein deficiency in the red cells of patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1992;80:399–405.
34.
van Kamp H, van Imhoff GW, de Wolf JT, et al: The effect of cyclosporine on haematological parameters in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995;89:79–82.
35.
Dacie J: Paroxysmal nocturnal haemoglobinuria. Sangre 1980;25:890–895.
36.
Hillmen P, Bessler M, Luzzatto L, et al: Long-term follow-up of 80 patients with PNH: 11 of 32 patients surviving 10 years achieve spontaneous remission (abstract). Blood 1993;82 (suppl 1):310a.
37.
Hillmen P, Lewis SM, Bessler M, et al: Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995;333:1253–1258.
38.
Kusminsky GD, Barazzutti L, Korin JD, et al: Complete response to antilymphocyte globulin in a case of aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome (letter). Am J Hematol 1988;29:123.
39.
Nakakuma H, Nagakura S, Kawaguchi T, et al: Persistence of affected T lymphoctes in long-term clinical remission in paroxysmal nocturnal hemoglobinuria. Blood 1994;84:3925–3928.
40.
Iwamoto N, Kawaguchi T, Horikawa K, et al: Preferential hematopoiesis by paroxysmal nocturnal hemoglobinuria clone engrafted in SCID mice. Blood 1996;87:4944–4948.
41.
Kawagoe K, Kitamura D, Okabe M, et al: Glycosylphosphatidylinositol-anchor-deficient mice: Implications for clonal dominance of mutant cells in paroxysmal nocturnal hemoglobinuria. Blood 1996;87:3600–3606.
42.
Keller P, Tremml G, Rosti V, et al: X inactivation and somatic cell selection rescue female mice carrying a Piga-null mutation. Proc Natl Acad Sci USA 1999;96:7479–7483.
43.
Maciejewski JP, Sloand EM, Sato T, et al: Impaired hematopoiesis in paroxysmal nocturnal hemoglobinuria / aplastic anemia is not associated with a selective proliferative defect in the glycosylphosphatidylinositol-anchored protein-deficient clone. Blood 1997;89:1173–1181.
44.
Brett SJ, Baxter G, Cooper H, et al: Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1 treatment. Int Immunol 1996;8:325–334.
45.
Hertenstein B, Wagner B, Bunjes D, et al: Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell Non-Hodgkin Lymphoma Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood 1995;86:1487–1492.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.